FXstreet.com

Daily Options Intelligence Report

1

1

Option traders say Broadcom bid for Emulex set to fail

Tue, Jun 30 2009, 16:35 GMT
by Andrew Wilkinson

Interactive Brokers LLC


ELX – Emulex Corp. - An interesting story has been developing at network gear-maker, Emulex in which the company is being courted by Broadcom Corporation. Two months ago Broadcom offered $9.25 per share for Emulex in an effort to integrate the two companies to develop new technologies for corporate data centers. The initial Broadcom overture came in December 2008 to which Emulex wrote a letter to the company stating it was not for sale, cutting off talks and writing a poison-pill provision into its bylaws. In an effort to convene a special shareholder meeting the company has boosted its offer to $11 per share and extended a tender offer deadline to July 1. Broadcom would then try to have the poison pill provision removed. However, shares at Emulex are down 8% to $10 today after the increase in Broadcom’s hostile bid. About three weeks ago we saw option traders scoop up put options at the July 10 strike for 45 cents apiece, while today there is increased interest in those same puts. We believe several investors are today banking gains on some established positions with puts trading hands at 75 cents today. Yet clearly there is a significant amount of fresh interest going on as investors speculate that Emulex means what it says and its shares will decline on account of the successful poison pill amendment. Some 27,000 puts are in play at the July 10 strike while the open interest reading of 17,000 has easily been surpassed. At the same August strike where only 44 contracts are open, defensive options have been bought more than 8,000 times so far today. As a result of the increased uncertainty surrounding this story options implied volatility has increased from 45 to 73%.

GERN – Geron Corp. – The biopharmaceutical company engaged in the development of human embryonic stem cell-based therapeutics appeared on our ‘hot by options volume’ market scanner this morning amid a 19% surge in shares to $7.96. Shares of GERN have climbed about 43% since the start of the year after the firm received FDA clearance to commence the world’s first human clinical trial using human embryonic stem cells to treat acute spinal cord injury. Today’s rally arrives on the heels of an announcement that Geron has forged a partnership with a General Electric Co. (GE) unit. The biopharmaceutical company asserted that it will collaborate with GE Healthcare to develop commercial products that use human stem cells. Optimistic option traders were seen buying into the bullish news by picking up nearly 2,000 calls at the now in-the-money July 7.5 strike price for a premium of 74 cents apiece. Profits will begin to amass for call-holders if shares can climb higher than the breakeven point at $8.24 by expiration. Investors who expect shares of GERN to break through the current 52-week high of $8.50, looked to the August 10 strike price where some 1,300 calls were purchased for 43 cents per contract. A rally of approximately 31% from the current price would result in profits to traders long the August 10 calls beginning at a share price of $10.43.

VALE – Vale S.A. – Shares of the Rio de Janeiro-based iron-ore producer have slipped approximately 1.5% today to $17.59 following earnings which were scheduled for release after yesterday’s closing bell. Despite the slight decline in price, our attention was drawn to the August contract where one investor chose to initiate a bullish reversal play. The trader looks to have sold 10,000 puts at the August 16 strike price for a premium of 65 cents apiece in order to finance the purchase of 10,000 calls at the August 20 strike for 65 cents each. The reversal was established at no cost to the investor who has positioned himself to benefit from upward movement in the price of the underlying. Profits will pad this option player’s pockets if shares can rally approximately 14% to breach the breakeven point at $20.00 by expiration in August. Any interim disappointment could see this investor having a block of one million of Vale’s shares put to him at a 9% discount to today’s share price.

NVDA – NVIDIA Corp. – The manufacturer of programmable graphics processors has realized a more than 2.5% decline in shares today to stand at $11.26. Wary of further bearish movement in the price of the underlying, option traders were seen scooping up put options in the near-term July contract. The July 11 strike price appears to have had about 20,000 puts purchased for an average premium of 33 cents apiece. Investors may be utilizing the puts to protect long positions in the stock or they could be looking to profit to the downside beneath the breakeven point at $10.67.

EXC – Exelon Corporation – The public utility holding company was launched onto our ‘most active by options volume’ market scanner after one trader played with 100,000 calls on the stock. Shares of the firm are currently higher by 1.5% to $51.22. It appears that this individual originally purchased 50,000 calls at the July 55 strike price for 40 cents apiece on June 25, 2009. Today he threw in the towel by selling-to-close all 50,000 lots for 20 cents. Apparently he does not see the July 55 calls landing in-the-money by expiration. Not yet ready to completely give up hope for a bullish rally, the trader accepted a loss of 20 cents per contract or $1,000,000, and reestablished a long position in the August contract. He paid a much more expensive 90 cents per contract, or $4,500,000, to get long of 50,000 calls at the August 55 strike. Shares must move higher than the breakeven point on the current call position in order to regain losses experienced on the closing sale in the July contract. EXC’s shares must move hard and fast in order to add about 10% to the current price. The investor will need the price of the underlying to reach the effective breakeven point at $56.10 to recoup losses and to breakeven by expiration in August.


Archive

Interactive Brokers LLC  | One Pickwick Plaza, Greenwich, CT 06830
http://www.interactivebrokers.com/ | info@interactivebrokers.com

Legal disclaimer and risk disclosure

The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither Interactive Brokers LLC nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither IB nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance is not necessarily indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.


Interested in forex trading? forex brokerage firms!


FOREX.com
Contact the broker/FDM
Open a demo account
ACM Advanced Currency Markets SA
Contact the broker/FDM
Open a demo account
Forex Club Financial Company
Contact the broker/FDM
Open a demo account
City Credit Capital (UK) Limited
Contact the broker/FDM
Open a demo account
Interbank FX, LLC
Contact the broker/FDM
Open a demo account

GET CASH BACK FOR YOUR TRADES!   Learn more about the Pip Rebate Program

Note: All information on this page is subject to change. The use of this website constitutes acceptance of our user agreement. Please read our privacy policy and legal disclaimer.

Trading foreign exchange on margin carries a high level of risk and may not be suitable for all investors. The high degree of leverage can work against you as well as for you. Before deciding to trade foreign exchange you should carefully consider your investment objectives, level of experience and risk appetite. The possibility exists that you could sustain a loss of some or all of your initial investment and therefore you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with foreign exchange trading and seek advice from an independent financial advisor if you have any doubts.

Opinions expressed at FXstreet.com are those of the individual authors and do not necessarily represent the opinion of FXstreet.com or its management. FXstreet.com has not verified the accuracy or basis-in-fact of any claim or statement made by any independent author: errors and Omissions may occur.

Any opinions, news, research, analyses, prices or other information contained on this website, by FXstreet.com, its employees, partners or contributors, is provided as general market commentary and does not constitute investment advice. FXstreet.com will not accept liability for any loss or damage, including without limitation to, any loss of profit, which may arise directly or indirectly from use of or reliance on such information.

©2009 "FXstreet.com. The Forex Market" All Rights Reserved.